Visby Medical Secures $65M to Revolutionize Rapid, On-the-Spot Infectious Disease Testing

Visby Medical is excited to announce a successful funding round, having raised $65,000,000 to accelerate its mission of revolutionizing infectious disease testing and treatment. The company is on a transformative journey to shift the paradigm in healthcare by enabling clinicians to test, talk with, and treat patients all in a single visit. At the heart of this transformation is Visby Medical’s proprietary, instrument-free, single-use PCR platform—the world's first of its kind that fits comfortably in the palm of your hand. This innovative technology rapidly detects serious respiratory and sexually transmitted infections, providing a crucial tool for healthcare providers who require quick, reliable diagnostic results at the point of care. The infusion of funds will be strategically used to scale up production capabilities to meet growing global demand, bolster further research and development initiatives, and refine the technology to cover an even broader spectrum of diagnostic applications. Additionally, the new funding will catalyze efforts to secure regulatory clearances and expand market operations into new regions, thus fostering stronger collaborations with leading healthcare institutions and providers worldwide. This significant capital raise not only reflects robust investor confidence in Visby Medical’s visionary approach, but also represents a key investment in the future of patient-centered care. By reducing diagnostic turnaround times, improving treatment accuracy, and ultimately enhancing patient outcomes, Visby Medical is poised to lead the change in how serious infectious diseases are managed across the globe. This funding milestone marks a pivotal next step in realizing a healthcare environment where rapid, on-the-spot diagnosis is not just a possibility, but a standard of care.